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ABSTRACT: A new family of organometallic p-cymene ruthenium(II) and
osmium(II) complexes conjugated to ethacrynic acid, a glutathione transferase
(GST) inhibitor, is reported. The ethacrynic acid moiety (either one or two) is
tethered to the arene ruthenium(II) and osmium(II) fragments via strongly
coordinating modiﬁed bipyridine ligands. The solid-state structure of one of
the complexes, i.e. [Os(η6-p-cymene)Cl][(4′-methyl-[2,2′-bipyridin]-4-yl)-
methyl-2-(2,3-dichloro-4-(2-methylenebutanoyl)phenoxy)acetate]Cl, was es-
tablished by single-crystal X-ray diﬀraction, corroborating the expected
structure. The complexes are eﬃcient inhibitors of GST P1-1, an enzyme
expressed in cancer cells and implicated in drug resistance, and are cytotoxic to
the GST-overexpressing chemoresistant A2780cisR ovarian cancer cell line.
■ INTRODUCTION
Resistance to chemotherapy, either intrinsic or acquired,
remains a serious obstacle in cancer treatment. Drug resistance
is a multifactorial process, and several basic mechanisms have
been identiﬁed, including enhanced drug eﬄux associated with
the P-glycoprotein, enhanced repair of drug-induced injury, and
enhanced detoxiﬁcation of drug intermediates, frequently
related to intracellular glutathione (GSH) and GSH-associated
enzymes.1−4 In particular, the overexpression of glutathione
transferases (GSTs) and eﬄux pumps in cancer cells reduces
the eﬃcacy of various anticancer drugs,1−4 and the search for
compounds capable of inhibiting GSTs and/or eﬄux pumps is
key to overcoming resistance to anticancer drugs.
GSTs are a family of homo- and heterodimeric cytosolic
enzymes that catalyze the conjugation of GSH with a variety of
exogenous and endogenous electrophiles and, consequently, are
involved in the inactivation of various electrophile-producing
anticancer agents. The products, in the form of mercapturates,
are subsequently eliminated from the cell.5 As GSH and the
GST superfamily play an important role in the mechanism of
anticancer drug resistance,2,6−8 including metal-based
drugs,9−15 eﬀorts have focused on the development of GST
inhibitors and GST-activated prodrugs as means of sensitizing
drug-resistant cancer cells to treatment.16−18 In this context,
ethacrynic acid ([2,3-dichloro-4-(2-methylene-1-oxobutyl)-
phenoxyl]acetic acid, EA-H; Figure 1) is a versatile, water-
soluble compound that modulates GST activity. EA-H
conjugation to GSH may occur in a spontaneous fashion or
via the catalytic action of the major classes of GST (α, μ, and
π), with the π isozyme being the most active.19 EA-H
potentiates the in vitro cytotoxicity of chemotherapeutic agents,
including alkylating agents such as melfalan,20−23 carmustine,24
mitomycin C,25 nitrogen mustards,17,26 and chlorambucil.19,27
EA-H induced sensitization of tumor cells to doxorubicin26,28
or cisplatin20,29,30 has also been reported. It was suggested that
EA-H may modulate the drug resistance of tumor cells not only
by inhibiting GST activity but also by inhibiting the export of
GSH conjugates of drugs from the cell by the multidrug
resistance protein.31
Platinum-based cancer drugs, such as cisplatin, are highly
eﬀective chemotherapeutic agents used extensively for the
treatment of solid tumors. Nevertheless, drug resistance is a
major obstacle for platinum-based chemotherapy, frequently
attributed to GSH-mediated detoxiﬁcation. GST enzymes,
speciﬁcally GST-π isozymes, are overexpressed in cisplatin-
resistant cell lines, and the inhibition of these enzymes can lead
to the reversal of drug resistance, as the combination of
cisplatin with EA-H resulted in improved activity against
cisplatin-resistant cells.20,29,30 The codelivery of EA-H and
DACHPt (a precursor of oxaliplatin) using biodegradable
nanoparticles results in an enhancement of the anticancer
eﬃcacy.32 In vivo, the nanoparticles demonstrated greater
anticancer eﬃcacy and less systemic toxicity, in comparison to a
combination therapy involving the free drugs.32 Recently, GST
inhibitor−anticancer drug conjugates have been reported, such
as ethacraplatin, a platinum(IV) metallodrug with two tethered
EA-H moieties.33−35 Ethacraplatin is a stronger inhibitor of
GST activity in live mammalian cells in comparison to either
cisplatin or EA-H alone,33 and the complex was shown to
reverse cisplatin resistance in the microsomal-GST-over-
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expressing MCF7 cell line.36 Platinum(II)−EA conjugates have
been also reported.34
Ruthenium compounds are promising alternatives to classical
platinum-based derivatives, and various ruthenium(III) and
ruthenium(II) complexes have been reported to exhibit
relevant antitumor activity. Two octahedral ruthenium(III)
complexes are under clinical development: i.e., trans-[HIm]-
[RuIIICl4(DMSO)(Im)] (Im = imidazole; NAMI-A), which is
essentially inactive on primary tumors but exhibits antimeta-
static activity,37−39 and trans-[HIn][RuIIICl4(Ind)2] (Ind =
indazole; KP1019), which is active against primary tumors.40,41
Organometallic ruthenium(II) arene complexes such as
[RuII(η6-p-cymene)(PTA)Cl2] (PTA = 1,3,5-triaza-7-
phosphatricyclo[3.3.1.1]decane; RAPTA-C)42−45 and
[RuII(η6-p-cymene)(en)Cl]+ (en = ethylenediamine;
RM175)46−48 (Figure 1) show considerable promise as
anticancer drugs in a number of preclinical models. Osmium-
(II)-based analogues of these compounds have also been
reported and show promising anticancer properties.48,49
One strategy used to modulate the medicinal properties of
ruthenium(II) arene complexes (and related osmium com-
pounds) is to tether a functional bioactive molecule to the
metal framework.50−57
Since bifunctional RAPTA-like compounds modiﬁed with EA
show promise as both GST inhibitors and anticancer agents
(Figure 1),33,58−62 we decided to prepare and evaluate a new
generation of dual-targeting ruthenium(II)− and osmium(II)−
EA conjugates related to the [RuII(η6-p-cymene)(en)Cl]+
structural motif, in which the en ligand is replaced by EA-
modiﬁed bipyridine ligands.
■ RESULTS AND DISCUSSION
The compounds described in this study were prepared
according to the routes shown in Schemes 1 and 2. Bipyridine
derivatives were modiﬁed with either one or two EA units (it
has been shown that organic compounds containing two EA
units are potent inhibitors of GST63,64). The route to the
bipyridine ligand with one EA moiety, i.e. L1, involves the
direct reaction of EA-H with 4-hydroxymethyl-4′-methyl-2,2′-
bipyridyl in the presence of 1-ethyl-3-(3-(dimethylamino)-
propyl)carbodiimide (EDCI) employed as a coupling agent and
4-(dimethylamino)pyridine (DMAP) catalyst. Subsequent
reaction of L1 with the dimers [M(η6-p-cymene)Cl]2Cl2 (M
= Ru, Os) aﬀords complexes 1a,b in good yield (Scheme 1).
The disubstituted EA-bipyridine ligand L2 was obtained
following a two-step procedure (Scheme 2) by initially
modifying EA-H with ethylene glycol to aﬀord L2a and
subsequent coupling to (2,2′-bipyridine)-5,5′-dicarboxylic acid.
Both steps employ EDCI and DMAP as the coupling agent and
catalyst, respectively. The resulting ligand, L2, reacts smoothly
with [M(η6-p-cymene)Cl]2Cl2 (M = Ru, Os) to aﬀord
complexes 2a,b.
Figure 1. Structure of ethacrynic acid (EA-H), RAPTA-C, RM175, and examples of ethacrynic acid−ruthenium(II) conjugates.
Scheme 1. Synthesis of Ligand L1 and Complexes 1a,b
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The ligands and complexes were fully characterized by 1H
and 13C NMR spectroscopy, mass spectrometry, IR spectros-
copy and elemental analysis (see the Experimental Section for
full details). The asymmetric bidentate ligand L1 induces
chirality at the metal center in 1a,b, resulting in loss of the 2-
fold symmetry of the η6-p-cymene moiety,65 and thus, 1a,b
were obtained as a racemic mixture.
The 1H NMR spectra of 1a,b contain four separate doublets
corresponding to the aromatic protons of the p-cymene ring
and two doublets attributable to the isopropyl group, one for
each methyl group, these resonances revealing the stereogenic
and chirotopic nature of the metal center (local C1
symmetry).65 The 1H NMR spectra of ligand L1 and the
corresponding complexes 1a,b exhibit peaks which show that
the protons α to the N atoms of the bipyridine unit are strongly
inﬂuenced by coordination to the metal ion; for L1 peaks
corresponding to the α protons appear at 8.65 and 8.53 ppm
and are observed at 9.41 and 9.28 ppm in 1a and at 9.34 and
9.22 ppm in 1b (for all of the compounds the signals observed
at higher frequencies may be attributed to the EA-modiﬁed
pyridine ring, whereas the peaks at lower frequencies
correspond to the pyridine ring substituted with the methyl
group). For the corresponding C atoms a similar shift to higher
frequencies is observed upon coordination of L1 (L1, 150.3 and
149.7 ppm; 1a, 156.7 and 156.1 ppm; 1b, 156.1 and 156.0
ppm). Coordination of ligand L2 to the metal centers leads to a
shift of all the peaks corresponding to the pyridine rings to
higher frequencies.
The structure of the compounds was further conﬁrmed by
electrospray ionization mass spectrometry. For the ligands L1
and L2 the representative parent peak appears at [M + H]+,
and for the complexes 1a,b and 2a,b the highest mass peak
corresponds to the [M − Cl]+ ion. Moreover, all of the
complexes are stable in DMSO solutions used for the biological
tests (see Figures S5 and S6 in the Supporting Information).
The crystal structure of 1b was established in the solid state
by single-crystal X-ray diﬀraction (Figure 2), conﬁrming the
expected structure. The structure comprises the classical three-
legged piano-stool arrangement. The coordination sphere of
the Os(II) ion contains an η6-p-cymene ring, the bidentate
ligand, and a chloride ligand. The average Os−η6 centroid
distance is 1.675(4) Å. The bipyridine ligand forms essentially a
planar ﬁve-membered chelating ring, the two pyridine rings of
the bipyridne ligands being almost coplanar (dihedral angle N1-
C-C−N2 2.2(11)°) (Figure S1). The the chelate bite angle
N1−Os−N2 is 76.6(3)°, and the N1−Os−Cl and N2−Os−Cl
angles are 84.6(2) and 86.1(2)°, respectively. The Os−Npy
bond lengths are 2.090(7) Å (for Os−N1) and 2.103(7) Å (for
Os−N2), and the Os−Cl bond length is 2.404(3) Å. The
packing in the crystal comprises intermolecular parallel-
displaced π−π stacking interactions between the bipyridine
ligands of two adjacent molecules (centroid−centroid distance
3.955 Å, Figure S2 in the Supporting Information). Another
key interaction in 1b comprises a three-center hydrogen bond
between the chloride counteranion (acting as a bifurcated
acceptor) and the hydrogen atoms of CH3OH and CHCl3
solvent molecules (see Figure S4 and Table S1 in the
Supporting Information for the parameters characterizing the
hydrogen bonding interaction).
Human GST P1-1 used for the experiments was expressed in
and puriﬁed from E. coli using a protocol reported earlier.66,67
The inhibitory activity of the compounds was investigated by
determining the residual catalytic activity of the enzyme using
Scheme 2. Synthesis of Ligand L2 and Complexes 2a,b
Figure 2. ORTEP representation of complex 1b (thermal ellipsoids
are 40% equiprobability envelopes, and H atoms are spheres of
arbitrary diameter).
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the CDNB-GSH (1-chloro-2,4-dinitrobenzene−glutathione)
assay.68 In brief, the enzyme was treated with varying
concentrations of complexes 1a,b and 2a,b to determine the
IC50 value i.e., the concentration at which 50% enzyme activity
is inhibited.
Complexes 1a,b (containing only one pendant ethacrynic
acid unit) inhibit GST P1-1 activity slightly more eﬃciently
than EA-H58 (see Table 1). Notably, complexes 2a,b,
containing two EA units, are more potent inhibitors of GST
P1-1. Furthermore, treatment with 2b results in almost
complete inhibition of GST P1-1 activity (residual activity
<5%) at the highest concentration tested (100 μm), whereas
there is more signiﬁcant residual GST P1-1 activity (∼14%)
after treatment with 1a,b at the same concentration (see Figure
S7 in the Supporting Information). These ﬁndings suggest a
role of the organometallic ruthenium fragment in the inhibition
of GST P1-1, potentially involving direct coordination of the
metal ion to the enzyme as established previously.58
The cytotoxicity of ligands L1 and L2, complexes 1a,b and
2a,b, and relevant control compounds was assessed in two
cancer cell lines (human ovarian carcinoma cisplatin-sensitive
A2780 and -resistant A2780cisR) and human embryonic kidney
(HEK-293) cells used as a model for normal cells. Cytotoxicity
studies were carried out at 37 °C for 72 h (Table 2 and Figure
S8 in the Supporting Information) using an MTT test (MTT =
3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bro-
mide) to monitor cell viability. All of the complexes are more
cytotoxic than RAPTA-C69 and its Os analogue, termed
OAPTA-C ([OsII(η6-p-cymene)(PTA)Cl2], PTA = 1,3,5-
triaza-7-phosphatricyclo[3.3.1.1]decane). Ligand L1 as well as
the complexes containing two EA units, i.e. 2a,b, present a
higher antiproliferative activity on all the tested cell lines in
comparison to EA-H. For complexes 1a,b with only one EA
unit a ca. 3-fold decrease in cytotoxicity against the cisplatin-
resistant ovarian carcinoma cells A2780cisR, in comparison to
the cisplatin-sensitive cells A2780 cells, is observed. For these
compounds the attachment of the organometallic MII-p-cymene
unit to ligand L1 leads to a decrease in cytotoxicity to both
A2780 and A2780cisR cells, whereas the Os(II) complex is
more active than the Ru(II) complex. The IC50 values
determined for 1a,b on the nontumoral HEK-293 cells are ca.
2-fold higher in comparison to those of the A2780 cells.
Interestingly, ligand L1, derivatized with one EA unit, has a
higher antiproliferative activity in comparison to EA-H on all
the tested cell lines, whereas attachment of two EA units in L2
is accompanied by a signiﬁcant decrease in cytotoxicity.
Attachment of an organometallic MII-p-cymene moiety to L2
in 2a,b leads to a signiﬁcant increase in the antiproliferative
activity toward all tested cell lines. The ruthenium complex
with two EA moieties, 2a, displays very similar IC50 values in
both the A2780 and A2780cisR cell lines (7.77 and 8.37 μM,
respectively), and the Os analogue is slightly less cytotoxic with
values of 9.31 and 15.7 μM, respectively. However, 2a,b are
both cytotoxic to the nontumorigenic HEK-293 cells with IC50
values of 6.16 and 12.8 μM, respectively. The relatively potent
cyctotoxicity of 2a,b cannot be attributed entirely to the ability
of the complexes to inhibit GST activity but is presumably also
in part due to the increased hydrophobicity of the complexes
relative to RAPTA-C and OAPTA-C, which potentially
enhances drug uptake and, consequently, their cytotoxic eﬀects.
Overall, complexes 1a,b are less cytotoxic in all three cell lines
than 2a,b. Since the former pair are chiral but obtained as a
racemic mixture, it is possible that the individual optical isomers
present diﬀerent antiproliferative activities. Indeed, it has been
previously shown that diﬀerent optical isomers of chiral-at-
metal or chiral-at-ligand ruthenium(II) and Os(II) arene
complexes may or may not exhibit similar cytotoxicities.70−73
Interestingly, in all three cell lines, for the Ru/Os pair 1a,b the
osmium complex is more cyctotoxic, whereas for the pair 2a,b
the ruthenium complex presents higher antiproliferative
activity. Such a diﬀerence is not entirely unexpected, as there
appears to be no clear correlation from the multitude of studies
reporting analogues based on these two metals.74
■ CONCLUSIONS
In summary, we have shown that incorporation of organo-
metallic p-cymene ruthenium(II) or osmium(II) centers to EA-
derived compounds enhances the inhibition of GST P1-1
activity, an enzyme expressed in cancer cells and responsible for
drug resistance. The enhanced inhibition is particularly notable
for 2a,b, in which the metal ion is located between two EA
moieties. These two compounds are also the most cytotoxic of
the series, displaying similar antiproliferative activity to both
A2780 and A2780cisR cells, indicative of overcoming GST-type
resistance in the latter cell line which is known to overexpress
GSTs.11 Interestingly, while there is no diﬀerence between the
pairs of ruthenium and osmium complexes in terms of GST P1-
1 inhibition and only a slight diﬀerence with respect to
antiproliferative activity, the metal ions appear to play a critical
role, i.e. in comparison to the free ligands, implying that direct
interactions with the enzyme might be involved.
Table 1. Inhibition of Human GST P1-1a
compound GST P1-1
RAPTA-C >200b
EA 12.0b
1a 9.06 ± 1.43
1b 9.53 ± 3.32
2a 3.96 ± 0.98
2b 3.98 ± 1.68
aIC50 values (μM) are given as the mean ± SD.
bValues taken from ref
58.
Table 2. IC50 Values (μM) Determined for RAPTA-C,
OAPTA-C, EA-H, Ligands L1 and L2, and Complexes 1a,b
and 2a,b towards Human Ovarian Cancer A2780 and
A2780cisR (Cisplatin Sensitive and Resistant) and
Immortalized Human Embryonic Kidney HEK-293 Cells
Using the MTT Assaya
compound A2780 A2780cisR HEK-293
RAPTA-C >200b >200b >1000b
OAPTA-C >200 >200 >200
EA 40 ± 3 53 ± 5 39 ± 1
L1 14.44 ± 1.97 24.3 ± 0.9 15.9 ± 5.1
1a 26.1 ± 1.6 84 ± 1 67 ± 2
1b 18.81 ± 0.85 59 ± 7 42.6 ± 1.0
L2 73 ± 3 639 ± 7 157 ± 20
2a 7.77 ± 0.01 8.37 ± 1.01 6.16 ± 1.79
2b 9.31 ± 2.62 15.7 ± 1.3 12.80 ± 0.18
cisplatin 0.95 11.14 16.51
aValues are given as the mean ± SD. bValues taken from ref 69.
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■ EXPERIMENTAL SECTION
General Experimental Conditions. RuCl3·3H2O was obtained
from Precious Metals Online, and all other chemicals were purchased
from from Aldrich, AlfaAesar, Acros, ABCR, or TCI Chemicals and
used without further puriﬁcation. Reactions were performed under an
inert atmosphere of N2 using Schlenk techniques with solvents dried
using drying columns. The dimers [Ru(η6-p-cymene)Cl]2Cl2 and
[Os(η6-p-cymene)Cl]2Cl2 were prepared and puriﬁed according to
literature procedures.75 1H (400.13 MHz) and 13C (100.62 MHz)
NMR spectra were recorded on a Bruker Avance II 400 spectrometer
at 298 K unless otherwise stated. The chemical shifts are reported in
parts per million (ppm) and referenced to residual solvent peaks
(CDCl3,
1H δ 7.26, 13C{1H} δ 77.16 ppm; MeOD-d4,
1H δ 3.31,
13C{1H} δ 49.00 ppm),76 and coupling constants (J) are reported in
hertz (Hz). IR spectra were recorded on a PerkinElmer Spectrum One
FT-IR spectrometer at room temperature. Electrospray ionization
mass spectra (ESI-MS) were obtained on a Thermo-Finnigan LCQ
Deca XP Plus quadropole ion-trap instrument operated in positive-ion
mode. Elemental analyses were carried out by the microanalytical
laboratory at the Institute of Chemical Sciences and Engineering
(EPFL). Melting points were determined using a SMP3 Stuart Melting
Point Apparatus and are uncorrected. Reactions were monitored by
TLC using Merck TLC silica gel coated aluminum sheets 60 F254 and
visualized with UV at 254 nm and KMnO4 stain. Compounds were
puriﬁed by column ﬂash chromatography on silica gel using the elution
systems indicated.
Syntheses of the Ligands. Synthesis of (4′-Methyl-[2,2′-
bipyridin]-4-yl)methyl-2-(2,3-dichloro-4-(2-methylenebutanoyl)-
phenoxy)acetate (L1). To a solution of ethacrynic acid (1.090 g, 1.2
equiv) in CH2Cl2 (100 mL) were added EDCI (0.804 g, 1.4 equiv), 4′-
methyl-[2,2′-bipyridin]-4-yl)methanol (0.600 g, 1 equiv), and DMAP
(0.110 g, 0.3 equiv). The reaction mixture was stirred at room
temperature for 24 h, and then the mixture was diluted with CH2Cl2
(50 mL) and washed with H2O (150 mL). The isolated organic phase
was further washed with brine (150 mL), dried over anhydrous
Na2SO4, ﬁltered, and concentrated under reduced pressure.
Puriﬁcation by ﬂash column chromatography using a CH2Cl2/
MeOH mixture as eluent aﬀorded the product as a colorless solid
(1.276 g, yield 88%): mp (°C): 71−72; Rf (CH2Cl2/MeOH 9.5/0.5):
0.543; 1H NMR (CDCl3) δH (ppm) 8.65 (1H, dd, O-CH2-(Py)C-CH-
CH-N, 3JH,H = 5.0 Hz,
4JH,H = 0.4 Hz), 8.53 (1H, d, CH3-(Py)C-CH-
CH-N, 3JH,H = 5.0 Hz), 8.40 (1H, m, O-CH2-(Py)C-CH-C-N), 8.25
(1H, m, CH3-(Py)C-CH-C-N), 7.24 (1H, dd, O-CH2-(Py)C-CH-CH-
N, 3JH,H = 5.0 Hz,
4JH,H = 1.7 Hz), 7.16 (1H, dd, CH3-(Py)C-CH-CH-
N, 3JH,H = 5.0 Hz,
4JH,H = 0.7 Hz), 7.10 (1H, d, (Ar)CH-C-(CO),
3JH,H = 8.5 Hz), 6.80 (1H, d, (Ar)CH-C-O-CH2-(CO), 3JH,H = 8.5
Hz), 5.90 (1H, t, cis (CHC)-CH2-CH3, 4JH,H = 1.4 Hz), 5.55 (1H, s,
trans (CHC)-CH2-CH3), 5.33 (2H, s, O-CH2-(Py)C-CH-CH-N),
4.88 (2H, s, (Ar)C-O-CH2-(CO)), 2.45 (2H, m, (CH2C)-CH2-
CH3,
3JH,H = 7.5 Hz), 2.44 (3H, s, CH3-(Py)C-CH-CH-N), 1.13 (3H,
t, (CH2C)-CH2-CH3, 4JH,H = 7.5 Hz); 13C NMR (CDCl3) δC
(ppm) 195.8 (1C, (Ar)C-(CO)-(CCH2)), 167.6 (1C, (Ar)C-O-
CH2-(CO)-O), 156.8 (1C, O-CH2-(Py)C-CH-C-N), 155.4 (1C,
(Ar)CH-C-O-CH2-(CO)), 155.3 (1C, CH3-(Py)C-CH-C-N), 150.3
(1C, O-CH2-(Py)C-CH-CH-N), 149.7 (1C, CH3-(Py)C-CH-CH-N),
149.0 (1C, CH3-CH2-(CCH2)), 148.7 (1C, O-CH2-(Py)C-CH-CH-
N), 144.9 (1C, CH3-(Py)C-CH-CH-N), 134.2 (1C, Cl-(Ar)C-C-(C
O)), 131.7 (1C, Cl-(Ar)C-C-(CO)), 128.7 (1C, (CH2C)-CH2-
CH3), 126.9 (1C, (Ar)CH−C-(CO)), 125.2 (1C, CH3-(Py)C-CH−
CH-N), 123.6 (1C, Cl-(Ar)C-C-O-CH2-(CO)), 122.3 (1C, CH3-
(Py)C-CH-C-N), 122.0 (1C, O-CH2-(Py)C-CH-CH-N), 119.6 (1C,
O-CH2-(Py)C-CH-C-N), 111.0 (1C, (Ar)CH-C-O-CH2-(CO)),
66.3 (1C, (Ar)C-O-CH2-(CO)), 65.6 (1C, O-CH2-(Py)C-CH-
CH-N), 23.5 (1C, (CH2C)-CH2-CH3), 21.4 (1C, CH3-(Py)C-CH-
CH-N), 12.5 (1C, (CH2C)-CH2-CH3); IR (ν, cm−1) 2925 (C−H,
CH2, CH3), 1760 (CO, ester), 1664 (CO, ketone, CC,
alkene), 1584, 1462, 1381 (ring skeleton CC, C−C, CN, C−N),
1291, 1258, 1186, 1076 (C-O, ester, ether), 820 (C−H aromatic); ESI-
MS(+) m/z 485.14 [M]+, calcd for C25H22Cl2N2O4 485.36 (the
isotopic pattern corresponds well to the calculated pattern). Anal.
Calcd for C25H22Cl2N2O4: C, 61.87; H, 4.57; N, 5.77. Found: C,
61.77; H, 4.63; N, 5.48.
Synthes i s o f 2 -Hydroxye thy l -2 - (2 ,3 -d i ch lo ro -4 - (2 -
methylenebutanoyl)phenoxy)acetate (L2a). To a solution of
ethacynic acid (4.000 g, 1 equiv) in CH2Cl2 (mL) were added
EDCI (3.035 g, 1.2 equiv), ethylene glycol (3 mL, 4 equiv), and
DMAP (0.322 g, 0.2 equiv). The reaction mixture was stirred at room
temperature for 24 h, and then the mixture was diluted with CH2Cl2
(50 mL) and washed with H2O (150 mL) and the isolated organic
phase was further washed with brine (150 mL), dried over anhydrous
Na2SO4, ﬁltered, and concentrated under reduced pressure.
Puriﬁcation by ﬂash column chromatography using a Hex/EtOAc
mixture as eluent aﬀorded the product as a white solid (3.459 g, yield
76%): Mp (°C) 94.5−95.5; Rf (Hex/AcOEt 4/6) 0.260; 1H NMR
(CDCl3) δH (ppm) 7.10 (1H, d, (Ar)CH-C-(CO), 3JH,H = 8.5 Hz),
6.78 (1H, d, (Ar)CH-C-O-CH2-(CO), 3JH,H = 8.5 Hz), 5.92 (1H, t,
cis (CHC)-CH2-CH3, 4JH,H = 1.4 Hz), 5.57 (1H, s, trans (CHC)-
CH2-CH3), 4.78 (2H, s, (Ar)C-O-CH2-(CO)-O), 4.30−4.32 (2H,
m, (CO)-O-CH2-CH2-OH), 3.80−3.83 (2H, m, (CO)-O-CH2-
CH2−OH), 2.42 (2H, m, (CH2C)-CH2-CH3, 3JH,H= 7.5 Hz), 1.11
(3H, t, (CH2C)-CH2-CH3, 3JH,H = 7.5 Hz); 13C NMR (CDCl3) δC
(ppm) 196.0 (1C, (Ar)C-(CO)-(CCH2)), 168.1 (1C, (Ar)C-O-
CH2-(CO)), 155.5 (1C, (Ar)CH-C-O), 150.2 (1C, CH3-CH2-
(C=CH2)), 134.0 (1C, Cl-(Ar)C-C-(CO)), 131.6 (1C, Cl-(Ar)C-C-
(CO)), 128.9 (1C, (CH2C)-CH2-CH3), 126.9 (1C, (Ar)CH−C-
(CO)), 123.4 (1C, Cl-(Ar)C-C-O-CH2-(CO)), 111.0 (1C, (Ar)
CH-C-O-CH2), 67.0 (1C, (Ar)C-O-CH2-(CO)-O), 66.3 (1C, (C
O)-O-CH2-CH2-OH), 60.8 (1C, (CO)-O-CH2-CH2-OH), 23.5
(1C, (CH2C)-CH2-CH3), 12.5 (1C, (CH2C)-CH2-CH3); IR (ν,
cm−1): 3509 (O−H); 2975−2880 (C−H, CH2, CH3), 1736 (CO,
ester), 1661 (CO, ketone, CC, alkene), 1587, 1471, 1383 (ring
skeleton CC, C−C); 1291, 1229, 1204, 1075 (C−O, ester, ether),
891 (C−H aromatic); ESI-MS(+): m/z 347.01 [M]+, calcd for
C15H16Cl2O5 347.19 (the isotopic pattern corresponds well to the
calculated pattern). Anal. Calcd for C15H16Cl2O5: C, 51.89; H, 4.65.
Found: C, 51.95; H, 4.69;
Synthesis of bis(2-(2-(2,3-dichloro-4-(2-methylenebutanoyl)-
phenoxy)acetoxy)ethyl)-(2,2′-bipyridine)-5,5′-dicarboxylate (L2).
To a suspension of [2,2′-bipyridine]-5,5′-dicarboxylic acid (0.765 g,
1 equiv) in a mixture of CH2Cl2 (20 mL) and (CH3)2NC(O)H (40
mL) were added EDCI (1.441 g, 2.4 equiv), L2a (2.500 g, 2.3 equiv),
and DMAP (0.230 g, 0.6 equiv). The reaction mixture was stirred at
room temperature for 48 h and then the mixture was concentrated to
dryness under reduced pressure and the crude product was solubilized
in CH2Cl2 (150 mL) and washed with H2O (150 mL). The isolated
organic phase was further washed with brine (150 mL), dried over
anhydrous Na2SO4, ﬁltered, and concentrated under reduced pressure.
Puriﬁcation by ﬂash column chromatography using a Hex/EtOAc
mixture as eluent aﬀorded the product as a white solid (0.875 g, yield
28%): mp (°C) 136−137; Rf (Hex/EtOAc 3/7 (v/v)) 0.729; 1H NMR
(CDCl3) δH (ppm) 9.28 (2H, s, 2xO-(CO)-(Py)C-CH-N), 8.60
(2H, d, 2 × (Py)N-C-CH-CH-C, 3JH,H = 8.2 Hz), 8.42 (2H, d, 2 ×
(Py)N-C-CH-CH-C, 3JH,H = 8.2 Hz), 7.10 (2H, d, (Ar)CH-C-(C
O), 3JH,H = 8.5 Hz), 6.81 (2H, d, (Ar)CH-C-O-CH2-(CO), 3JH,H =
8.5 Hz), 5.90 (2H, s, 2 × cis (CHC)-CH2-CH3), 5.56 (2H, s, 2 ×
trans (CHC)-CH2-CH3), 4.82 (4H, s, 2 × (Ar)C-O−CH2-(C
O)), 4.63 (8H, m, 2 × (Ar)C-O-CH2-(CO)−O-CH2-CH2, 2 ×
(Ar)C-O-CH2-(CO)-O-CH2-CH2), 2.43 (4H, m, 2 × (CH2C)-
CH2-CH3,
3JH,H = 7.4 Hz), 1.12 (6H, t, 2 × (CH2C)-CH2-CH3,
4JH,H = 7.4 Hz);
13C NMR (CDCl3) δC (ppm) 195.8 (2C, 2 × (Ar)C-
(CO)-(CCH2)), 167.9 (2C, 2 × (Ar)C-O-CH2-(CO)), 164.9
(2C, 2 × (Py)N−CH-C-(CO)-O), 158.6 (2C, 2 × (Py)N-C-CH-
CH-C), 155.5 (2C, 2 × (Ar)CH-C-O), 150.8 (2C, 2 × (Py)N-CH−C-
(CO)), 150.3 (2C, 2xCH3-CH2-(C=CH2)), 138.4 (2C, 2 × (Py)N−
C-CH-CH−C), 134.2 (2C, 2 × Cl-(Ar)-C-C-(CO)), 131.7 (2C, 2 ×
Cl-(Ar)-C-C-(CO)), 128.7 (2C, 2 × (CH2C)-CH2-CH3), 126.9
(2C, 2 × (Ar)CH−C-(CO)), 126.0 (2C, 2 × (Py)N−CH-C-(C
O)-O), 123.6 (2C, 2 × Cl-(Ar)C−C-O), 121.6 (2C, 2 × (Py)N−C-
CH-CH-C), 111.0 (2C, 2 × (Ar)CH-C-O-CH2-(CO)), 66.3 (2C, 2
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× (Ar)C-O-CH2-(CO)), 63.2 (2C, 2 × (Ar)C-O-CH2-(CO)-O-
CH2-CH2), 62.9 (2C, 2 × (Ar)C-O-CH2-(CO)-O-CH2−CH2), 23.5
(2C, 2 × (CH2C)-CH2−CH3), 12.5 (2C, 2 × (CH2C)-CH2-
CH3); IR (ν, cm
−1) 2967 (C−H, CH2, CH3), 1762 (CO, ester),
1720 (CO, ester), 1663 (CO, ketone, CC, alkene), 1585,
1466, 1384 (ring skeleton CC, C−C, CN, C−N), 1267, 1190,
1111, 1079 (C−O, ester, ether), 802 (C−H aromatic); ESI-MS(+) m/
z 903.11 [M + H]+, 925.09 [M + Na]+, calcd for C42H36Cl4N2O12
902.55 (the isotopic pattern corresponds well to the calculated
pattern). Anal. Calcd for C42H36Cl4N2O12: C, 55.89; H, 4.02; N, 3.10.
Found: C, 56.00; H, 4.12; N, 3.09.
General Procedure for the Synthesis of the Ru(II)- and Os(II)-
Arene Complexes. To a solution of the appropriate dimer, [Ru(η6-p-
cymene)Cl]2Cl2 or [Os(η
6-p-cymene)Cl]2Cl2, in CH2Cl2 (10 mL) was
added a solution of the appropriate ligand in CH2Cl2 (25 mL), and the
obtained mixture was stirred at room temperature in the dark for 24 h.
The solvent was removed under reduced pressure, the crude product
was redissolved in CH2Cl2 (1 mL), and the product was precipitated
with Et2O (5 mL) and then successively washed with warm Et2O (4 ×
50 mL) and hexane (2 × 25 mL). The resulting solid was dried under
high vacuum.
Synthesis of [Ru(η6-p-cymene)Cl][(4′-methyl-[2,2′-bipyridin]-4-
yl)methyl-2-(2,3-dichloro-4-(2-ethylenebutanoyl)phenoxy)acetate]-
Cl (1a). Complex 1a was prepared following the general procedure
starting from [Ru(η6-p-cymene)Cl]2Cl2 (0.222 g, 1 equiv) and ligand
L1 (0.352 g, 2 equiv), to aﬀord an orange solid (0.537 g, yield 94%):
mp (°C) 149−151 dec; 1H NMR (MeOD-d4) δH (ppm) 9.41 (1H, d,
O-CH2-(Py)C-CH-CH-N,
3JH,H = 5.9 Hz), 9.28 (1H, d, CH3-(Py)C-
CH-CH-N, 3JH,H = 5.9 Hz), 8.46 (1H, m, O-CH2-(Py)C-CH-C-N),
8.39 (1H, m, CH3-(Py)C-CH-C-N), 7.61 (1H, dd, O-CH2-(Py)C-CH-
CH-N, 3JH,H = 5.9 Hz,
4JH,H = 1.1 Hz), 7.59 (1H, dd, CH3-(Py)C-CH-
CH-N, 3JH,H = 5.9 Hz,
4JH,H = 1.7 Hz), 7.21 (1H, d, (Ar)CH-C-(C
O), 3JH,H = 8.6 Hz), 7.11 (1H, d, (Ar)CH-C-O-CH2-(CO), 3JH,H =
8.6 Hz), 6.09−6.11 (2H, m, 2xCH3-(Ar)C-CH-CH-C), 6.04 (1H, t, cis
(CHC)-CH2-CH3, 4JH,H = 1.3 Hz), 5.86 (1H, m, CH3-(Ar)C-CH-
CH-C, 3JH,H = 8.5 Hz), 5.84 (1H, m, CH3-(Ar)C-CH-CH-C,
3JH,H =
8.5 Hz), 5.59 (1H, s, trans (CHC)-CH2-CH3), 5.51 (2H, s, O-CH2-
(Py)C-CH-CH-N), 5.14 (2H, s, (Ar)C-O-CH2-(CO)), 2.63 (3H, s,
CH3-(Py)C-CH-CH-N), 2.62 (1H, sept, (Ar)C-CH-CH-C-
CH(CH3)2,
3JH,H = 6.9 Hz), 2.45 (2H, m, (CH2C)-CH2-CH3,
3JH,H = 7.4 Hz), 2.26 (3H, s, CH3-(Ar)C-CH-CH-C), 1.15 (3H, t,
(CH2C)-CH2-CH3, 4JH,H = 7.4 Hz), 1.04 (3H, d, (Ar)C-CH-CH-C-
CH-CH3,
3JH,H = 6.9 Hz), 1.02 (3H, d, (Ar)C-CH-CH-C-CH-CH3,
3JH,H = 6.9 Hz);
13C NMR (MeOD-d4) δC (ppm) 197.3 (1C, (Ar)C-
(CO)-(CCH2)), 169.1 (1C, (Ar)C-O-CH2-(CO)), 157.0 (1C,
O-CH2-(Py)C-CH-C-N), 156.7 (1C, O-CH2-(Py)C-CH-CH-N),
156.5 (1C, (Ar)CH-C-O-CH2-(CO)), 156.1 (1C, CH3-(Py)C-
CH-CH-N), 155.5 (1C, CH3-(Py)C-CH-C-N), 154.2 (1C, CH3-CH2-
(C=CH2)), 151.6 (1C, O-CH2-(Py)C-CH-CH-N), 151.1 (1C, CH3-
(Py)C-CH-CH-N), 134.9 (1C, Cl-(Ar)C-C-(CO)), 131.9 (1C, Cl-
(Ar)-C-C-(CO)), 130.1 (1C, (CH2C)-CH2-CH3), 129.9 (1C,
(Ar)CH-C-(CO)), 128.4 (1C, CH3-(Py)C-CH-CH-N), 126.5 (1C,
CH3-(Py)C-CH-C-N), 125.9 (1C, O-CH2-(Py)C-CH-CH-N), 123.8
(1C, Cl-(Ar)C-C-O), 122.7 (1C, O-CH2-(Py)C-CH-C-N), 112.6 (1C,
(Ar)CH-C-O-CH2-(CO)), 105.8 (1C, CH3-(Ar)C-CH-CH-C),
105.6 (1C, CH3-(Ar)C-CH-CH-C), 88.2 (1C, CH3-(Ar)C-CH-CH-
C), 88.0 (1C, CH3-(Ar)C-CH-CH-C), 85.5 (1C, CH3-(Ar)C-CH-CH-
C), 85.3 (1C, CH3-(Ar)C-CH-CH-C), 67.1 (1C, (Ar)C-O-CH2-(C
O)), 65.2 (1C, O-CH2-(Py)C-CH-CH-N), 32.3 (1C, (Ar)CH-CH-C-
CH(CH3)2), 24.5 (1C, (CH2C)-CH2-CH3), 22.3 (2C, (Ar)CH-CH-
C-CH(CH3)2), 21.3 (1C, CH3-(Py)C-CH-CH-N), 19.0 (1C, CH3-
(Ar)C-CH-CH-C), 13.0 (1C, (CH2C)-CH2-CH3); IR (ν, cm−1)
3060−2872 (C−H, CH2, CH3), 1763 (CO, ester), 1661, 1620
(CO, ketone, CC, alkene), 1580, 1470, 1384 (ring skeleton C
C, C−C, CN, C−N), 1284, 1210, 1075 (C-O, ester, ether), 800
(C−H aromatic); ESI-MS(+): m/z 756.06 [M − Cl]+, calcd for
C35H36Cl3N2O4Ru
+ 756.10 (the isotopic pattern corresponds well to
the calculated pattern). Anal. Calcd for C35H36Cl4N2O4Ru: C, 53.11;
H, 4.58; N, 3.54. Found: C, 53.16; H, 4.58; N, 3.34.
Synthesis of [Os(η6-p-cymene)Cl][(4′-methyl-[2,2′-bipyridin]-4-
yl)methyl-2-(2,3-dichloro-4-(2-ethylenebutanoyl)phenoxy)acetate]-
Cl (1b). Complex 1b was prepared following the general procedure
starting from [Os(η6-p-cymene)Cl]2Cl2 (0.291 g, 1 equiv) and ligand
L1 (0.357 g, 1 equiv), to aﬀord a yellow solid (0.597 g, yield 92%): mp
(°C): 159−161 dec; 1H NMR (MeOD-d4) δH (ppm) 9.34 (1H, d, O-
CH2-(Py)C-CH-CH-N,
3JH,H = 6.0 Hz), 9.22 (1H, d, CH3-(Py)C-CH-
CH-N, 3JH,H = 5.9 Hz), 8.56 (1H, m, O-CH2-(Py)C-CH-C-N), 8.48
(1H, m, CH3-(Py)C-CH-C-N), 7.58 (1H, dd, O-CH2-(Py)C-CH-CH-
N, 3JH,H = 6.0 Hz,
4JH,H = 1.4 Hz), 7.56 (1H, dd, CH3-(Py)C-CH-CH-
N, 3JH,H = 5.9 Hz,
4JH,H = 1.9 Hz), 7.21 (1H, d, (Ar)CH-C-(CO),
3JH,H = 8.6 Hz), 7.11 (1H, d, (Ar)CH-C-O-CH2-(CO), 3JH,H = 8.6
Hz), 6.32 (1H, m, CH3-(Ar)C-CH-CH-C), 6.30 (1H, m, CH3-(Ar)C-
CH-CH-C), 6.04 (1H, t, cis (CHC)-CH2-CH3, 4JH,H = 0.9 Hz), 6.01
(1H, d, CH3-(Ar)C-CH-CH-C,
3JH,H = 6.2 Hz), 5.99 (1H, d, CH3-
(Ar)C-CH-CH-C, 3JH,H = 6.2 Hz), 5.59 (1H, s, trans (CHC)-CH2-
CH3), 5.56 (2H, s, O-CH2-(Py)C-CH-CH-N), 5.14 (2H, s, (Ar)C-O-
CH2-(CO)), 2.70 (3H, s, CH3-(Py)C-CH-CH-N), 2.48 (1H, sept,
(Ar)C-CH-CH−C-CH(CH3)2, 3JH,H = 6.9 Hz), 2.45 (2H, m, (CH2
C)-CH2-CH3,
3JH,H = 7.4 Hz), 2.33 (3H, s, CH3-(Ar)C-CH-CH-C),
1.15 (3H, t, (CH2C)-CH2-CH3, 4JH,H = 7.4 Hz), 0.98 (3H, d,
(Ar)C-CH-CH-C-CH-CH3,
3JH,H = 6.9 Hz), 0.97 (3H, d, (Ar)C-CH-
CH-C-CH-CH3,
3JH,H = 6.9 Hz);
13C NMR (MeOD-d4) δC (ppm)
197.3 (1C, (Ar)C-(CO)-(CCH2)), 169.1 (1C, (Ar)C-O-CH2-
(CO)), 157.4 (1C, O-CH2-(Py)C-CH-C-N), 157.0 (1C, CH3-
(Py)C-CH-C-N), 156.6 (1C, O-CH2-(Py)C-CH-CH-N), 156.3 (1C,
(Ar)CH-C-O-CH2-(CO)), 156.0 (1C, CH3-(Py)C-CH-CH-N),
154.3 (1C, CH3-CH2-(CCH2)), 151.7 (1C, O-CH2-(Py)C-CH-
CH-N), 151.0 (1C, CH3-(Py)C-CH-CH-N), 134.9 (1C, Cl-(Ar)C-C-
(CO)), 131.9 (1C, Cl-(Ar)C-C-(CO)), 130.6 (1C, (CH2C)-
CH2-CH3), 130.1 (1C, (Ar)CH−C-(CO)), 128.4 (1C, CH3-(Py)C-
CH-CH-N), 127.3 (1C, CH3-(Py)C-CH-C-N), 125.9 (1C, O-CH2-
(Py)C-CH−CH-N), 123.8 (1C, Cl-(Ar)C-C-O), 122.9 (1C, O-CH2-
(Py)C-CH-C-N), 112.6 (1C, (Ar)CH-C-O-CH2-(CO)), 98.8 (1C,
CH3-(Ar)C-CH-CH-C), 96.6 (1C, CH3-(Ar)C-CH-CH-C), 79.6 (1C,
CH3-(Ar)C-CH-CH-C), 79.5 (1C, CH3-(Ar)C-CH-CH-C), 75.4 (1C,
CH3-(Ar)C-CH-CH-C), 75.2 (1C, CH3-(Ar)C-CH-CH-C), 67.1 (1C,
(Ar)C-O-CH2-(CO)), 65.2 (1C, O-CH2-(Py)C-CH-CH-N), 32.6
(1C, (Ar)CH-CH-C-CH(CH3)2), 24.5 (1C, (CH2C)-CH2-CH3),
22.6 (2C, (Ar)CH-CH-C-CH(CH3)2), 21.3 (1C, CH3-(Py)C-CH-CH-
N), 18.9 (1C, CH3-(Ar)C-CH-CH-C), 13.0 (1C, (CH2C)-CH2-
CH3); IR (ν, cm
−1) 2961−2924 (C−H, CH2, CH3), 1762 (CO,
ester), 1663, 1621 (CO, ketone, CC, alkene), 1580, 1468, 1382
(ring skeleton CC, C−C, CN, C−N), 1283, 1195, 1074 (C−O,
ester, ether), 801 (C−H aromatic); ESI-MS(+) m/z 845.11 [M −
Cl]+, calcd for C35H36Cl3N2O4Os
+ 845.26 (the isotopic pattern
corresponds well to the calculated pattern). Anal. Calcd for
C35H36Cl4N2O4Os: C, 47.73; H, 4.12; N, 3.18. Found: C, 47.93; H,
4.12; N, 2.99.
Synthesis of [Ru(η6-p-cymene)Cl][bis(2-(2-(2,3-dichloro-4-(2-
methylenebutanoyl)phenoxy)acetoxy)ethyl)-(2,2′-bipyridine)-5,5′-
dicarboxylate]Cl (2a). Complex 2a was prepared following the general
procedure starting from [Ru(η6-p-cymene)Cl]2Cl2 (0.085 g, 1 equiv)
and ligand L2 (0.250 g, 2 equiv), to aﬀord a yellow solid (0.263 g, yield
79%): mp (°C): 97−99; 1H NMR (CDCl3) δH (ppm) 9.75 (2H, s, 2 ×
O-(CO)-(Py)C-CH-N), 9.27 (2H, d, 2 × (Py)N−C-CH-CH-C,
3JH,H = 7.8 Hz), 8.59 (2H, d, 2 × (Py)N−C-CH-CH-C, 3JH,H = 7.8
Hz), 7.11 (2H, d, 2 × (Ar)CH-C-(CO), 3JH,H = 8.4 Hz), 6.93 (2H,
d, 2 × (Ar)CH-C-O-CH2-(CO), 3JH,H = 8.4 Hz), 6.15 (2H, d,
2xCH3-(Ar)C-CH-CH-C,
3JH,H = 5.4 Hz), 6.01 (2H, d, 2 × CH3-
(Ar)C-CH-CH-C, 3JH,H = 5.4 Hz), 5.92 (2H, s, 2 × cis (CHC)-
CH2-CH3), 5.55 (2H, s, 2 × trans (CHC)-CH2-CH3), 5.02 (2H, d,
2 × (Ar)C-O−CH-(CO)-O-(CH2)2-O, 1JH,H = 17.7 Hz), 4.91 (2H,
d, 2 × (Ar)C-O−CH-(CO)-O-(CH2)2−O, 1JH,H = 17.7 Hz), 4.54−
4.83 (8H, m, 2 × (Ar)C-O-CH2-(CO)-O-CH2-CH2, 2 × (Ar)C-O-
CH2-(CO)-O-CH2-CH2), 2.75 (1H, sept, (Ar)C-CH-CH−C-
CH(CH3)2,
3JH,H = 6.7 Hz), 2.42 (4H, m, 2 × (CH2C)-CH2-
CH3,
3JH,H = 7.4 Hz), 2.21 (3H, s, CH3-(Ar)C-CH-CH-C), 1.07−1.15
(12H, m, 2 × (CH2C)-CH2-CH3, (Ar)C-CH-CH-C-CH(CH3)2);
13C NMR (CDCl3) δC (ppm) 195.8 (2C, 2 × (Ar)C-(CO)-(C
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CH2)), 168.3 (2C, 2 × (Ar)C-O-CH2-(CO)), 162.3 (2C, 2 ×
(Py)N−CH-C-(C=O)-O), 157.1 (2C, 2 × (Py)N-C-CH-CH-C),
156.1 (2C, 2 × (Py)N-CH−C-(CO)), 155.3 (2C, 2 × (Ar)CH-C-
O), 150.2 (2C, 2 × CH3-CH2-(C=CH2)), 140.8 (2C, 2 × (Py)N−C-
CH-CH−C), 134.0 (2C, 2 × Cl-(Ar)C-C-(CO)), 131.4 (2C, 2 ×
Cl-(Ar)C-C-(CO)), 129.5 (2C, 2 × (Ar)CH-C-(CO)), 129.0
(2C, 2 × (CH2C)-CH2-CH3), 127.1 (2C, 2 × (Py)N-C-CH-CH-C),
126.6 (2C, 2 × (Py)N-CH-C-(CO)-O), 123.2 (2C, 2 × Cl-(Ar)C-
C-O), 111.3 (2C, 2 × (Ar)CH-C-O-CH2-(CO)), 106.3 (1C, CH3-
(Ar)C-CH-CH-C), 103.5 (1C, CH3-(Ar)C-CH-CH-C), 87.2 (2C, 2 ×
CH3-(Ar)C-CH-CH-C), 85.1 (2C, 2 × CH3-(Ar)C-CH−CH-C), 66.5
(2C, 2 × (Ar)C-O-CH2-(CO)), 64.7 (2C, 2 × (Ar)C-O-CH2-(C
O)-O-CH2-CH2), 62.8 (2C, 2 × (Ar)C-O-CH2-(CO)-O-CH2-
CH2), 31.4 (1C, (Ar)CH-CH-C-CH(CH3)2), 23.5 (2C, 2 ×
(CH2C)-CH2-CH3), 22.3 (2C, (Ar)CH-CH-C-CH(CH3)2), 18.9
(1C, CH3-(Ar)C-CH-CH-C), 12.5 (2C, 2 × (CH2C)-CH2-CH3);
IR (ν, cm−1) 2966 (C−H, CH2, CH3), 1731 (CO, ester), 1661
(CO, ketone, CC, alkene), 1582, 1468, 1382 (ring skeleton C
C, C−C, CN, C−N), 1286, 1194, 1119, 1077 (C−O, ester, ether),
804 (C−H aromatic); ESI-MS(+) m/z 1173.08 [M − Cl]+, calcd for
C52H50Cl5N2O12Ru
+ 1173.29 (the isotopic pattern corresponds well to
the calculated pattern). Anal. Calcd for C52H50Cl6N2O12Ru: C, 51.67;
H, 4.17; N, 2.32. Found: C, 51.71; H, 4.19; N, 2.23.
Synthesis of [Os(η6-p-cymene)Cl][bis(2-(2-(2,3-dichloro-4-(2-
methylenebutanoyl)phenoxy)acetoxy)ethyl)-(2,2′-bipyridine)-5,5′-
dicarboxylate]Cl (2b). Complex 2b was prepared following the
general procedure starting from [Os(η6-p-cymene)Cl]2Cl2 (0.110 g, 1
equiv) and ligand L2 (0.250 g, 2 equiv), to aﬀord an orange-red solid
(0.332 g, yield 93%): mp (°C) 89−91; 1H NMR (CDCl3) δH (ppm)
9.65 (2H, s, 2 × O-(CO)-(Py)C-CH-N), 9.55 (2H, d, 2 × (Py)N-
C-CH-CH-C, 3JH,H = 5.2 Hz), 8.61 (2H, d, 2 × (Py)N-C-CH-CH-C,
3JH,H = 5.2 Hz), 7.11 (2H, d, 2 × (Ar)CH-C-(CO), 3JH,H = 8.1 Hz),
6.91 (2H, d, 2 × (Ar)CH-C-O-CH2-(CO), 3JH,H = 8.1 Hz), 6.28
(2H, m, 2 × CH3-(Ar)C-CH-CH-C), 6.10 (2H, m, 2 × CH3-(Ar)C-
CH-CH-C), 5.91 (2H, s, 2 × cis (CHC)-CH2-CH3), 5.55 (2H, s, 2
× trans (CHC)-CH2-CH3), 4.97 (2H, d, 2 × (Ar)C-O-CH-(C
O)-O-(CH2)2−O, 1JH,H = 16.4 Hz), 4.87 (2H, d, 2 × (Ar)C-O−CH-
(CO)-O-(CH2)2-O, 1JH,H = 16.4 Hz), 4.57−4.79 (8H, m, 2 × O-
CH2-(CO)-O-CH2-CH2, 2 × O-CH2-(CO)-O-CH2-CH2), 2.60
(1H, sept, (Ar)C-CH-CH-C-CH(CH3)2,
3JH,H = 6.2 Hz), 2.41 (4H, m,
2 × (CH2C)-CH2-CH3, 3JH,H = 7.4 Hz), 2.27 (3H, s, CH3-(Ar)C-
CH-CH-C), 1.10 (6H, t, 2 × (CH2C)-CH2-CH3), 1.03 (6H, d,
(Ar)C-CH-CH-C-CH(CH3)2);
13C NMR (CDCl3) δC (ppm) 195.8
(2C, 2 × (Ar)C-(C=O)-(CCH2)), 168.2 (2C, 2 × (Ar)C-O-CH2-
(CO)), 162.1 (2C, 2 × (Py)N-CH-C-(CO)-O), 158.0 (2C, 2 ×
(Py)N-C-CH-CH-C), 155.9 (2C, 2 × (Py)N-CH−C-(CO)), 155.3
(2C, 2 × (Ar)−CH-C-O), 150.1 (2C, 2xCH3-CH2-(C=CH2)), 140.9
(2C, 2 × (Py)N−C-CH-CH−C), 133.9 (2C, 2 × Cl-(Ar)-C-C-(C
O)), 131.3 (2C, 2 × Cl-(Ar)-C-C-(CO)), 130.1 (2C, 2 × (Ar)-
CH−C-(CO)), 129.1 (2C, 2 × (CH2C)-CH2-CH3), 127.1 (2C, 2
× (Py)N-C-CH−CH-C), 126.9 (2C, 2 × (Py)N-CH-C-(CO)-O),
123.1 (2C, 2 × Cl-(Ar)C-C-O), 111.3 (2C, 2 × (Ar)CH-C-O-CH2-
(CO)), 97.2 (1C, CH3-(Ar)C-CH-CH-C), 96.9 (1C, CH3-(Ar)C-
CH-CH-C), 78.9 (2C, 2 × CH3-(Ar)C-CH-CH-C), 75.4 (2C, 2 ×
CH3-(Ar)C-CH−CH-C), 66.4 (2C, 2 × (Ar)C-O-CH2-(CO)), 64.7
(2C, 2 × (Ar)C-O-CH2-(CO)-O-CH2-CH2), 62.8 (2C, 2 × (Ar)C-
O-CH2-(CO)-O-CH2-CH2), 31.4 (1C, (Ar)CH-CH-C-CH(CH3)2),
23.4 (2C, 2 × (CH2C)-CH2-CH3), 22.5 (2C, (Ar)CH-CH-C-
CH(CH3)2), 18.8 (1C, CH3-(Ar)C-CH-CH-C), 12.4 (2C, 2 ×
(CH2C)-CH2-CH3); IR (ν, cm−1) 2967 (C−H, CH2, CH3), 1731
(CO, ester), 1662 (CO, ketone, CC, alkene), 1583, 1469,
1382 (ring skeleton CC, C−C, CN, C−N), 1287, 1195, 1120,
1078 (C−O, ester, ether), 805 (C−H aromatic); ESI-MS(+) m/z
1262.14 [M-Cl]+, calcd for C52H50Cl5N2O12Os
+ 1262.45 (the isotopic
pattern corresponds well to the calculated pattern). Anal. Calcd for
C52H50Cl6N2O12Os: C, 48.12; H, 3.88, N, 2.16. Found: C, 48.13; H,
3.92; N, 2.06.
X-ray Structure Determination for 1b. Diﬀraction data were
recorded at low temperature (100(2) K) using Mo Kα radiation on a
Bruker APEX II CCD diﬀractometer equipped with a κ geometry
goniometer.
The data sets were reduced by EvalCCD77 and then corrected for
absorption.78 The solution and reﬁnement were performed by
SHELXT and SHELXL2014 (release 7).79 The crystal structures
were reﬁned using full-matrix least squares based on F2 with all non-
hydrogen atoms anisotropically deﬁned. Hydrogen atoms were placed
in calculated positions by means of the “riding” model. Additional
electron density found in the diﬀerence Fourier map of the compound
(due to disordered solvent) was treated by the SQUEEZE algorithm of
PLATON80 and then treated by the ABIN instruction in
SHELXL2014. Crystal data and structure reﬁnement details are
given in Table 3.
Protein Expression and Puriﬁcation. Human GST P1-1 wild-
type was expressed in Escherichia coli and puriﬁed as previously
described.66 The reaction was monitored by spectrophotometry at 340
nm, corresponding to the absorbance maximum of glutathione-2,4-
dinitrobenzene conjugate (ε340 = 9.6 M
−1 cm−1).81 Spectrophoto-
metric measurements were performed using a double-beam Cary UV−
vis 4000 spectrophotometer (Kontron Instruments) equipped with a
thermostated cuvette compartment.
GST P1-1 Inhibition Assay. The residual enzymatic activity of
GST P1-1 was assayed by spectrophotometry in 100 mM phosphate
buﬀer, pH 6.5, in the presence of variable amounts of compound 1a,
Table 3. Crystal Data and Structure Reﬁnement Details for
1b
chem formula C35H36Cl4N2O4Os·CHCl3·CH3OH
formula wt 1032.07
temp (K) 100(2)
wavelength (Å) 0.71073
cryst syst triclinic
space group P1̅
unit cell dimens
a (Å) 11.7589(16)
b (Å) 12.2253(7)
c (Å) 16.4565(10)
α (deg) 70.951(7)
β (deg) 79.147(8)
γ (deg) 75.472(6)
V (Å3) 2150.0(4)
Z 2
Dcalcd (g/cm
3) 1.594
μ (mm−1) 3.442
F(000) 1024
cryst size (mm) 0.319 × 0.212 × 0.102
θ range for data collection (deg) 1.893−27.498
index ranges
h −15 to +15
k −15 to +15
l −21 to +21
no. of measd rﬂns 27952
no. of indep rﬂns 9668 (R(int) = 0.0690)
completeness to θ = 25.242° (%) 99.2
abs cor semiempirical from equivalents
max and min transmission 0.7456 and 0.3830
reﬁnement method full-matrix least squares on F2
no. of data/restraints/params 9668/187/543
GOF 1.052
R1 (I > 2σ(I)) 0.0696
wR2 (I > 2σ(I)) 0.1595
R1 (all data) 0.0996
wR2 (all data) 0.1808
largest diﬀ peak and hole (e Å−3) 2.802 and −1.706
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1b, 2a, or 2b (from 1 to 100 μM), predissolved in DMSO, 1 mM GSH
(glutathione), and 1 mM CDNB (1-chloro-2,4-dinitrobenzene), at 25
°C. The IC50 values for the inhibition of GST P1-1 were determined
by ﬁtting a plot of residual GST activity against the inhibitor
concentrations with a sigmoidal dose−response function using Graph
PAD Prism (Graph PAD Software, San Diego, CA).
Cell Culture. Human A2780 and A2780cisR ovarian carcinoma
cells were obtained from the European Centre of Cell Cultures
(ECACC, U.K.). The resistance of the A2780cisR cells was maintained
by a monthly treatment with cisplatin (2 μM/one 4 day passage).
Nontumorigenic HEK-293 cells were provided by the Institute of
Pathology, CHUV, Lausanne, Switzerland. A2780 and A2780cisR were
grown in RPMI 1640 medium supplemented with GlutaMAX
(Gibco), and HEK-293 cells were grown in DMEM medium, all
containing heat-inactivated fetal calf serum (FCS, Sigma, USA) (10%)
and antibiotics (penicillin (100 U/mL):streptomycin (100 μg/mL),
working concentration 1:100, Life Technologies, Gibco) at 37 °C and
CO2 (5%).
Antiproliferative Activity in Vitro. Cytotoxicity was determined
using the MTT assay (MTT = 3-(4,5-dimethyl-2-thiazolyl)-2,5-
diphenyl-2H-tetrazolium bromide). Cells were seeded in 96-well
plates as monolayers with 100 μL of cell solution per well and
preincubated for 24 h in the cell medium. Compounds were prepared
as DMSO solutions that were rapidly dissolved in the culture medium
and serially diluted to the appropriate concentration to give a ﬁnal
DMSO concentration of 0.5%. A 100 μL portion of the drug solution
was added to each well, and the plates were incubated for another 72
h. Subsequently, MTT (5 mg/mL solution) was added to the cells and
the plates were incubated for a further 4 h. The culture medium was
aspirated, and the purple formazan crystals formed by the
mitochondrial dehydrogenase activity of vital cells were dissolved in
DMSO. The optical density, directly proportional to the number of
surviving cells, was quantiﬁed at 540 nm using a multiwell plate reader,
and the fraction of surviving cells was calculated from the absorbance
of untreated control cells. Evaluation was based on means from two
independent experiments, each comprising three microcultures per
concentration level.
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